|
Quantification of NDMA in Olmesartan by HPLC-MS/MS
|
|
0
|
315
|
June 14, 2022
|
|
亚硝胺杂质分析方法验证的可接受标准
|
|
3
|
505
|
June 2, 2022
|
|
Sample preparation - erythromycin estolate
|
|
1
|
285
|
May 3, 2022
|
|
Absolute Quantitationof N‑Nitrosamines by Coulometric Mass Spectrometry
|
|
0
|
312
|
April 27, 2022
|
|
Pharmaceutical samples containing NDMA, NDEA, or NDEA
|
|
2
|
353
|
April 23, 2022
|
|
Risk assessment for nitrosated pharmaceuticals: A future perspective
|
|
2
|
593
|
April 22, 2022
|
|
Publications review on Nitrosamines (Analytical) 2022
|
|
1
|
1084
|
March 24, 2022
|
|
New proposed GC-NPD method for nitrosamines
|
|
5
|
567
|
March 22, 2022
|
|
Looking for PT of nitrosaminesI
|
|
6
|
312
|
March 17, 2022
|
|
Nitrosamines in Ophthalmic solutions using LC-Tandem MS
|
|
0
|
321
|
March 11, 2022
|
|
NMP in Rifampicin by LC-MS/MS
|
|
1
|
411
|
March 10, 2022
|
|
26 September 2022 is around the corner!
|
|
2
|
335
|
February 22, 2022
|
|
Nitrosamine quantification by GC-MS & LC-MS
|
|
0
|
324
|
February 16, 2022
|
|
New method for amine analysis in pharmaceuticals
|
|
0
|
277
|
February 15, 2022
|
|
Standardized method for Nitrite impurities?
|
|
4
|
445
|
February 15, 2022
|
|
Anyone experienced low level interference/ contamination issues with NDBA during method development?
|
|
2
|
837
|
February 3, 2022
|
|
Risk assessment for Nitrosated pharmaceutical : a future prespective in drug development
|
|
0
|
361
|
February 2, 2022
|
|
Should we expand to Analytical Category? need your feedback!
|
|
20
|
841
|
January 18, 2022
|
|
Nitrosamines Formation as Artefact... What are the Challenges?
|
|
11
|
756
|
December 22, 2021
|
|
Referential Testing Methods by FDA's presentation
|
|
0
|
282
|
November 18, 2021
|
|
FDA-published method for Rifampin & Rifapentine DS/DP
|
|
0
|
395
|
November 17, 2021
|
|
NDMA Analytics in Metformin -Methods and Pitfalls?
|
|
0
|
375
|
October 18, 2021
|